TY - JOUR
T1 - Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery
AU - Fahmy, Sherif Ashraf
AU - Dawoud, Alyaa
AU - Zeinelabdeen, Yousra Ahmed
AU - Kiriacos, Caroline Joseph
AU - Daniel, Kerolos Ashraf
AU - Eltahtawy, Omar
AU - Abdelhalim, Miriam Mokhtar
AU - Braoudaki, Maria
AU - Youness, Rana A.
A2 - Giangaspero, Felice
N1 - © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
PY - 2022/10/26
Y1 - 2022/10/26
N2 - Pediatric primary brain tumors represent a real challenge in the oncology arena. Besides the psychosocial burden, brain tumors are considered one of the most difficult-to-treat malignancies due to their sophisticated cellular and molecular pathophysiology. Notwithstanding the advances in research and the substantial efforts to develop a suitable therapy, a full understanding of the molecular pathways involved in primary brain tumors is still demanded. On the other hand, the physiological nature of the blood–brain barrier (BBB) limits the efficiency of many available treatments, including molecular therapeutic approaches. Hydrogen Sulfide (H 2S), as a member of the gasotransmitters family, and its synthesizing machinery have represented promising molecular targets for plentiful cancer types. However, its role in primary brain tumors, generally, and pediatric types, particularly, is barely investigated. In this review, the authors shed the light on the novel role of hydrogen sulfide (H 2S) as a prominent player in pediatric brain tumor pathophysiology and its potential as a therapeutic avenue for brain tumors. In addition, the review also focuses on the challenges and opportunities of several molecular targeting approaches and proposes promising brain-delivery strategies for the sake of achieving better therapeutic results for brain tumor patients.
AB - Pediatric primary brain tumors represent a real challenge in the oncology arena. Besides the psychosocial burden, brain tumors are considered one of the most difficult-to-treat malignancies due to their sophisticated cellular and molecular pathophysiology. Notwithstanding the advances in research and the substantial efforts to develop a suitable therapy, a full understanding of the molecular pathways involved in primary brain tumors is still demanded. On the other hand, the physiological nature of the blood–brain barrier (BBB) limits the efficiency of many available treatments, including molecular therapeutic approaches. Hydrogen Sulfide (H 2S), as a member of the gasotransmitters family, and its synthesizing machinery have represented promising molecular targets for plentiful cancer types. However, its role in primary brain tumors, generally, and pediatric types, particularly, is barely investigated. In this review, the authors shed the light on the novel role of hydrogen sulfide (H 2S) as a prominent player in pediatric brain tumor pathophysiology and its potential as a therapeutic avenue for brain tumors. In addition, the review also focuses on the challenges and opportunities of several molecular targeting approaches and proposes promising brain-delivery strategies for the sake of achieving better therapeutic results for brain tumor patients.
KW - Review
KW - brain tumors
KW - pediatric cancers
KW - hydrogen sulfide
KW - neuro-oncology
KW - nanocarriers
KW - nanotechnology
KW - microRNAs
KW - siRNAs
KW - RNA-technology
KW - molecular pathways
UR - http://www.scopus.com/inward/record.url?scp=85143352282&partnerID=8YFLogxK
U2 - 10.3390/cancers14215244
DO - 10.3390/cancers14215244
M3 - Review article
C2 - 36358663
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 21
M1 - 5244
ER -